Leerink Swann Comments on Sucampo Pharmaceuticals, Inc.’s FY2017 Earnings (SCMP)
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) – Research analysts at Leerink Swann decreased their FY2017 earnings per share estimates for shares of Sucampo Pharmaceuticals in a note issued to investors on Friday. Leerink Swann analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings per share of $1.02 for the year, down from their prior estimate of $1.04. Leerink Swann currently has a “Outperform” rating and a $15.00 target price on the stock. Leerink Swann also issued estimates for Sucampo Pharmaceuticals’ FY2020 earnings at $1.81 EPS and FY2021 earnings at $1.93 EPS.
SCMP has been the topic of several other reports. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a report on Tuesday, October 17th. UBS AG decreased their price objective on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, October 12th. Roth Capital set a $30.00 price objective on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Maxim Group reiterated a “buy” rating and issued a $23.00 price objective (up from $21.00) on shares of Sucampo Pharmaceuticals in a report on Tuesday, August 8th. Finally, TheStreet downgraded shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a report on Wednesday, August 2nd. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $16.50.
Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at $10.70 on Monday. Sucampo Pharmaceuticals has a fifty-two week low of $9.30 and a fifty-two week high of $17.55. The company has a market cap of $495.52, a price-to-earnings ratio of 7.23, a price-to-earnings-growth ratio of 3.27 and a beta of 1.38. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The firm had revenue of $61.27 million for the quarter, compared to the consensus estimate of $58.05 million. During the same period in the previous year, the company earned $0.30 earnings per share. The company’s quarterly revenue was up 5.9% on a year-over-year basis.
In related news, major shareholder Sachiko Kuno sold 1,000,000 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $12.00, for a total value of $12,000,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jason Patrick Meyenburg purchased 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The stock was acquired at an average price of $12.13 per share, for a total transaction of $48,520.00. Following the completion of the purchase, the insider now directly owns 30,228 shares of the company’s stock, valued at approximately $366,665.64. The disclosure for this purchase can be found here. Corporate insiders own 4.13% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. HPM Partners LLC acquired a new position in shares of Sucampo Pharmaceuticals in the second quarter valued at about $1,307,000. Louisiana State Employees Retirement System grew its stake in shares of Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 100 shares in the last quarter. Karp Capital Management Corp acquired a new position in shares of Sucampo Pharmaceuticals in the first quarter valued at about $119,000. Nine Chapters Capital Management LLC bought a new stake in Sucampo Pharmaceuticals during the third quarter worth about $127,000. Finally, First Citizens Bank & Trust Co. bought a new stake in Sucampo Pharmaceuticals during the second quarter worth about $116,000. Institutional investors and hedge funds own 55.76% of the company’s stock.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.